Jin‐Ji Yang
0000-0002-8498-0119
Publication & Citation Trends
Publications
0 total
PP01.42: Efficacy and Multi-omics Insights of Immune Checkpoint Inhibitors in NSCLC with Leptomeningeal Metastasis
Cited by 0
Semantic Scholar
Cerebrospinal fluid circulating tumor DNA profiling for risk stratification and matched treatment of central nervous system metastases
Cited by 13
Semantic Scholar
First-Line Camrelizumab versus Placebo Plus Chemotherapy with or without Radiotherapy for Brain Metastases in Non-Small-Cell Lung Cancer: The CTONG 2003 Randomized Placebo-Controlled Trial.
Cited by 10
Semantic Scholar
Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study.
Cited by 2
Semantic Scholar
Comparing the effect of traditional and novel tyrosine kinase inhibitors for epidermal growth factor receptor exon 20 insertions by molecular dynamics simulation
Cited by 0
Semantic Scholar
Lipid-associated macrophages for osimertinib resistance and leptomeningeal metastases in NSCLC.
Cited by 19
Semantic Scholar
Combination of Cytologic Findings and Circulating Tumor DNA From Cerebrospinal Fluid Revealed SCLC Transformation in Patients With Leptomeningeal Metastases of Lung Adenocarcinoma OA
Cited by 1
Semantic Scholar
Plasma EBV quantification is associated with the efficacy of immune checkpoint blockade and disease monitoring in patients with primary pulmonary lymphoepithelioma‐like carcinoma OA
Cited by 6
Semantic Scholar
Research Topics
Lung Cancer Treatments and Mutations
(225)
Lung Cancer Research Studies
(84)
Cancer Genomics and Diagnostics
(57)
Cancer Immunotherapy and Biomarkers
(52)
Lung Cancer Diagnosis and Treatment
(45)
Affiliations
Novartis (Switzerland)
Xinjiang Medical University
Hangzhou Normal University
National Taiwan University
Chinese University of Hong Kong